Attenuation of Staphylococcus aureus–Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Immunology

• Publication date

  2015-09-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.1500966PMID 26342032PMCID PMC4592844
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neutrophil-Mediated Phagocytosis of Staphylococcus aureus

  2014cited by this paper
• Where does a Staphylococcus aureus vaccine stand?

  2014cited by this paper
• The inflammatory response in sepsis.

  2013cited by this paper
• Phagocytosis Escape by a Staphylococcus aureus Protein That Connects Complement and Coagulation Proteins at the Bacterial Surface

  2013cited by this paper
• Recurrent infections and immune evasion strategies of Staphylococcus aureus.

  2012cited by this paper
• Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of Staphylococcal immune evasion proteins.

  2012cited by this paper
• Staphylococcus aureus Virulence Is Enhanced by Secreted Factors That Block Innate Immune Defenses

  2012cited by this paper
• Exploring Staphylococcus aureus pathways to disease for vaccine development

  2012cited by this paper
• Binding of Efb from Staphylococcus aureus to Fibrinogen Blocks Neutrophil Adherence*

  2011cited by this paper
• A MRSA-terious enemy among us: Boosting MRSA vaccines

  2011cited by this paper
• Complement: a key system for immune surveillance and homeostasis

  2010cited by this paper
• Molecular mechanisms of complement evasion: learning from staphylococci and meningococci

  2010cited by this paper
• Allosteric inhibition of complement function by a staphylococcal immune evasion protein

  2010cited by this paper
• Development trends for human monoclonal antibody therapeutics

  2010cited by this paper
• Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues

  2009cited by this paper
• Staphylococcus aureus infections.

  2009cited by this paper
• Waves of resistance: Staphylococcus aureus in the antibiotic era

  2009cited by this paper
• Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus.

  2009cited by this paper
• Vaccination and passive immunisation against Staphylococcus aureus.

  2008cited by this paper
• Solution insights into the structure of the Efb/C3 complement inhibitory complex as revealed by lysine acetylation and mass spectrometry

  2008cited by this paper
• Molecular engineering and design of therapeutic antibodies.

  2008cited by this paper
• Designer monoclonal antibodies as drugs: the state of the art

  2008cited by this paper
• The anti-inflammatory activities of Staphylococcus aureus.

  2007cited by this paper
• A structural basis for complement inhibition by Staphylococcus aureus

  2007influential reference
• Safety of IGIV therapy and infusion-related adverse events

  2007cited by this paper
• Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality.

  2007cited by this paper
• Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

  2007cited by this paper
• Characterization of Ehp, a Secreted Complement Inhibitory Protein from Staphylococcus aureus*

  2007cited by this paper
• Staphylococcal complement evasion by various convertase-blocking molecules

  2007cited by this paper
• Analyzing a kinetic titration series using affinity biosensors.

  2006cited by this paper
• Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus.

  2006cited by this paper
• An optimized system for expression and purification of secreted bacterial proteins.

  2006cited by this paper
• Staphylococcal innate immune evasion.

  2005cited by this paper
• Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases

  2005influential reference
• Comparison of Antibody Repertoires against Staphylococcus aureus in Healthy Individuals and in Acutely Infected Patients

  2005cited by this paper
• Role of C5a in inflammatory responses.

  2005influential reference
• Immune evasion by staphylococci

  2005cited by this paper
• Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.

  2002cited by this paper
• Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.

  2001cited by this paper
• Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.

  2000influential reference
• Multiple Binding Sites in the Interaction between an Extracellular Fibrinogen-binding Protein from Staphylococcus aureus and Fibrinogen*

  1998cited by this paper
• Staphylococcus aureus infections.

  1998cited by this paper
• Lack of the extracellular 19-kilodalton fibrinogen-binding protein from Staphylococcus aureus decreases virulence in experimental wound infection

  1996cited by this paper
• A rapid FPLC method for purification of the third component of human and guinea pig complement.

  1991cited by this paper
• Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.

  1985cited by this paper

• How does Staphylococcus aureus successfully colonize the nasal cavity

  2025cites this paper
• Inflammatory mechanisms and intervention strategies for sepsis‐induced myocardial dysfunction

  2023cites this paper
• Antibodies to coagulase of Staphylococcus aureus crossreact to Efb and reveal different binding of shared fibrinogen binding repeats

  2023cites this paper
• Extracellular fibrinogen-binding protein (Efb), a key immune evasion protein of Staphylococcus aureus and a potential therapeutic target

  2022cites this paper
• Antibodies to Coagulase of Staphylococcus aureus crossreact to Efb and reveal different binding of shared Fibrinogen binding repeats

  2022cites this paper
• Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci

  2021cites this paper
• Bactericidal fully human single‐chain fragment variable antibodies protect mice against methicillin‐resistant Staphylococcus aureus bacteraemia

  2021cites this paper
• Complement levels in patients with bloodstream infection due to Staphylococcus aureus or Gram-negative bacteria

  2020cites this paper
• Janus face of complement-driven neutrophil activation during sepsis.

  2018cites this paper
• New milestones ahead in complement-targeted therapy.

  2016cites this paper